CYTOMX THERAPEUTICS INC. - COMMON STOCK

CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023

01 مايو 2023 16:01:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

25 أبريل 2023 16:05:01 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update

27 مارس 2023 16:15:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023

22 مارس 2023 19:23:33 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Present at Upcoming March Investor Conferences

28 فبراير 2023 16:05:01 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

26 يناير 2023 07:00:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference

17 يناير 2023 16:05:00 بحسب Nasdaq GlobeNewswire

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

05 يناير 2023 16:05:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities

05 يناير 2023 16:05:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023

22 ديسمبر 2022 17:00:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

20 ديسمبر 2022 17:00:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium

07 ديسمبر 2022 16:30:00 بحسب Nasdaq GlobeNewswire

CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

17 نوفمبر 2022 07:00:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

08 نوفمبر 2022 16:10:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b (CX-801) at the SITC 2022 Annual Meeting

07 نوفمبر 2022 16:15:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Present at Upcoming November Investor Conferences

02 نوفمبر 2022 16:15:01 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Report Third Quarter 2022 Financial Results on November 8, 2022

01 نوفمبر 2022 08:00:01 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody® Therapeutic BMS-986249

12 سبتمبر 2022 08:00:02 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Presents Overview of Conditionally-Activated Antibody-Drug Conjugate (ADC) Programs Including Next Generation EpCAM-Targeting CX-2051

07 سبتمبر 2022 18:05:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

04 أغسطس 2022 16:15:00 بحسب Nasdaq GlobeNewswire